01:16 10/31 UTC — Bearish
U.S. markets closed out the week under significant selling pressure, highlighted by Intel's 28.6% drop and broad tech sector weakness. Disappointing semiconductor guidance and rising concerns over unsustainable AI capital expenditures led to risk-off positioning. Defensive growth names like Eli Lilly stood out with strong earnings beats, while broader index levels test critical support entering the weekend.
Markets are experiencing heavy selling pressure led by the semiconductor and tech sectors following Intel's historic earnings drop and guidance reduction. Rising skepticism around massive AI infrastructure capex—highlighted by S&P's negative outlook rating on Meta—is driving capital rotation toward defensive balance sheets like Eli Lilly and Apple. Technical levels are under stress as indices test key support levels amid volatile pre-election and economic data uncertainty.
Outlook
Bearish · 1-3Days (Medium)
Base — Likely
Indices remain volatile under pressure from semiconductor weakness and tech capex concerns, testing SPY 750 support before seeing selective dip-buying.
Bear — Possible
A breach below key support (SPY 750, QQQ 683) accelerates institutional derisking due to broad macro and AI monetization worries.
Bull — Unlikely
A strong market reversal occurs if key tech earnings like Apple outperform significantly and push SPY back above 761.
Hot tickers
- INTC Bearish — Plunged ~28.6% in its worst day since 1974 after lowering next-quarter earnings guidance and missing estimates.
- LLY Bullish — Crushed Q3 earnings expectations and raised full-year guidance driven by explosive GLP-1 drug demand.
- PGEN Bearish — Dropped ~27% after hours following FDA approval for competitor Inovio's RRP drug.
- META Bearish — S&P Global Ratings revised outlook to negative citing extreme AI capex ($135B-$145B) impacting free cash flow.
- SPOT Bullish — Exhibited strong relative strength against a down market alongside heavy bullish options flow ($25M).
Themes
- AI Capex Skepticism & Tech Repricing
- Semiconductor Sector Weakness
- Biotech Competitive Shifts Post-FDA Decisions
Risks
- Escalating AI infrastructure expenditures depressing corporate free cash flow
- Spillover weakness across semiconductor supply chains following Intel's results
- Heightened vulnerability to major market support level breaches (SPY 750 / QQQ 683)
Get digest by email Open live dashboard All digests About FC Global